Moody Lynn Lieberson & Walker LLC Increases Stock Position in Merck & Co., Inc. $MRK

Moody Lynn Lieberson & Walker LLC increased its holdings in Merck & Co., Inc. (NYSE:MRK) by 121.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 110,547 shares of the company’s stock after acquiring an additional 60,711 shares during the quarter. Moody Lynn Lieberson & Walker LLC’s holdings in Merck & Co., Inc. were worth $14,205,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. in the fourth quarter valued at $25,000. Abound Financial LLC purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $26,000. Prosperity Bancshares Inc acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $26,000. High Note Wealth LLC boosted its stake in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after buying an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst sentiment improved: Daiwa Securities upgraded Merck to “outperform” and set a $143 price target, while Argus raised its target to $145 and maintained a “buy” rating. These targets imply additional upside from recent trading levels. Daiwa Securities upgrade
• Positive Sentiment: RSV expansion opportunity: The FDA and European Medicines Agency accepted supplemental applications for broader use of ENFLONSIA to prevent RSV in vulnerable young children. The regulatory reviews could expand Merck’s growth beyond oncology and help diversify the portfolio ahead of Keytruda’s future patent expirations. Merck RSV regulatory review article
• Positive Sentiment: Estimates edged higher: Erste Group raised its FY2026 earnings forecast for Merck to $2.75 per share from $2.70, broadly aligning with the $2.76 consensus estimate. The company also recently exceeded quarterly revenue and adjusted earnings expectations, reporting $16.61 billion in revenue.
• Positive Sentiment: Core business remains solid: Keytruda, oncology and animal health supported quarterly growth, while the company continues investing in its pipeline. Merck also declared its regular $0.85 quarterly dividend, equivalent to a $3.40 annualized payout.
• Neutral Sentiment: Vaccine-policy uncertainty: Reports that the administration may seek to split the MMR vaccine into separate shots could create headlines around the broader vaccine market, but experts say the proposal lacks scientific support and is unlikely to advance. MMR vaccine policy article
• Negative Sentiment: Repeated insider selling: EVP Richard R. Deluca sold roughly 45,000 shares across transactions from August 6 through August 12 for approximately $6.7 million. Although he retained a substantial position, the sales may weigh modestly on sentiment.
• Negative Sentiment: Longer-term risks persist: Analysts continue to flag falling estimates, a high valuation and upcoming patent expirations, particularly the eventual loss of Keytruda exclusivity. These issues could limit upside unless Merck’s pipeline and newer products offset the expected revenue pressure.

Merck & Co., Inc. Stock Up 2.1%

MRK stock opened at $133.10 on Thursday. The stock has a market capitalization of $328.38 billion, a PE ratio of 106.48, a price-to-earnings-growth ratio of 5.62 and a beta of 0.19. The company has a fifty day moving average of $124.94 and a 200-day moving average of $119.64. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $135.05.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The business’s revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts expect that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on MRK shares. Scotiabank boosted their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research report on Tuesday, June 30th. Morgan Stanley increased their price objective on Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Citigroup assumed coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price on the stock. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday. Finally, Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a report on Wednesday. Fifteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $135.50.

Insiders Place Their Bets

In other news, EVP Richard R. Deluca sold 20,784 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the transaction, the executive vice president directly owned 134,703 shares of the company’s stock, valued at approximately $17,569,312.29. This represents a 13.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president directly owned 18,212 shares in the company, valued at $2,344,248.64. This represents a 50.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 137,923 shares of company stock worth $17,908,943. Company insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.